封面
市场调查报告书
商品编码
1752983

糖组学治疗学全球市场

Glycomic Therapeutics

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 401 Pages | 商品交期: 最快1-2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年,全球糖组学治疗市场规模将达到 3,957 亿美元

全球糖代谢疗法市场规模预计在2024年为1,627亿美元,到2030年将达到3,957亿美元,2024年至2030年的复合年增长率为16.0%。分离类药物是本报告分析的细分市场之一,预计其复合年增长率为17.5%,到分析期结束时规模将达到2787亿美元。合成类药物在分析期内的复合年增长率预计为12.9%。

美国市场规模估计为 443 亿美元,中国市场预计复合年增长率为 21.4%

美国糖代谢疗法市场规模预计2024年达到443亿美元。作为世界第二大经济体,中国预计到2030年市场规模将达到874亿美元,在2024-2030年的分析期间内,复合年增长率为21.4%。其他值得关注的区域市场包括日本和加拿大,预计在分析期间内,这两个市场的复合年增长率分别为11.6%和14.4%。在欧洲,预计德国市场的复合年增长率约为12.7%。

全球「糖组学治疗」市场—主要趋势与驱动因素摘要

为什么糖组学治疗学会成为精准医疗的前沿?

糖组学疗法——针对并操控参与细胞信号传导、免疫和疾病进展的聚醣(糖复合物)——代表了生物医学的前沿。糖组学在发炎、肿瘤生长、病原体识别和免疫调节等过程中发挥关键作用。与传统的小分子或基因疗法不同,醣质学提供了全新的生物学见解,可用于诊断、监测和治疗癌症、自体免疫疾病和感染疾病等复杂疾病。随着製药业转向个人化和系统级方法,分析和靶向聚醣结构的能力为超越传统分子标靶的新型高选择性治疗方法打开了大门。糖组学疗法越来越被视为充分发挥精准医疗潜力的下一步。

哪些科学技术进步促进了基于聚醣的药物的发展?

分析化学、糖工程和生物资讯学的突破对于糖组学疗法的实用化至关重要。先进的质谱和高通量聚醣分析技术使研究人员能够以前所未有的深度和速度来表征聚醣结构。糖工程技术可以修饰糖蛋白以增强治疗效果、降低免疫抗原性或延长药物半衰期。此外,CRISPR 和其他基因编辑工具正被用于控制工程细胞株中的糖基化途径,以控製糖蛋白的产生。整合糖组学、蛋白质组学和基因组数据的生物资讯平台帮助研究人员识别疾病特异性聚醣特征,从而实现更好的药物标靶和生物标记发现。这些技术协同效应正在迅速将醣体学从学术领域转变为商业性驱动的治疗领域。

全球临床应用与治疗管道如何发展?

目前,Glycomic Therapeutics 已涉足多个治疗领域,尤其是肿瘤学、免疫学和病毒学。针对癌细胞异常聚醣表现的癌症免疫疗法(例如唾液酸配体和聚醣依赖性免疫查核点)正在积极研究中。在罕见遗传疾病领域,优化聚醣表现的酵素替代疗法已改善了治疗效果。两家公司也正在开发以聚醣为基础的抗病毒药物和疫苗,包括针对病毒刺突蛋白上聚醣屏障的 COVID-19 候选药物。发炎和自体免疫疾病也是一个重点,因为聚醣介导的细胞黏附和讯号传导在免疫细胞行为中起着关键作用。北美目前在研究资金和生物製药投资方面处于领先地位,但欧洲的研究机构和新兴企业也积极参与其中。亚太地区,尤其是日本和韩国,正成为聚醣科学和治疗方法开发的重要创新中心。

Glycomic Therapeutics 的市场驱动力和挑战是什么?

糖组学治疗市场的成长是由精准医疗需求的不断增长、对糖生物学理解的不断扩展以及对新型生技药品投资的不断增加所驱动。製药公司正在投资该领域,以多样化他们的治疗组合,并透过新的作用机制满足未满足的医疗需求。政府研究经费和公私合作也在推动基础糖科学研究进入临床阶段。然而,挑战依然存在,包括聚醣结构的复杂性、缺乏标准化的分析平台、商业性先例有限、具有高研发成本。此外,基于糖药物的药物监管途径仍在不断发展,这可能会延迟核准。儘管存在这些障碍,但该领域仍具有巨大的潜力。随着科学认识的进步和商业性途径的成熟,糖组学治疗有望成为未来药物开发的基础组成部分。

部分

类别(分离类、合成类)、结构(醣蛋白结构、唾液酸靶向结构、蛋白多醣结构、Glico靶向结构、锚蛋白和肝素基聚醣结构、鞘脂靶向结构、其他结构)、适应症(血栓症/化学预防、贫血、白内障、高雪氏症、MPS-1/IV、癌症、阿兹海默症、其他)

受访公司范例(44家值得关注的公司)

  • Acuitas Therapeutics
  • Agilent Technologies Inc.
  • Alzheon Inc.
  • AMS Bio
  • Arrakis Therapeutics
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Bio-Techne Corporation
  • Bruker Corporation
  • F. Hoffmann-La Roche Ltd.
  • Genovis AB
  • GlaxoSmithKline plc
  • GlycoMar Limited
  • Grifols SA
  • Halozyme Therapeutics Inc.
  • ICON plc
  • Intellihep Ltd.
  • Ludger Ltd.
  • Merck KGaA
  • New England Biolabs Inc.
  • Protalix Biotherapeutics Inc.
  • RayBiotech Life Inc.
  • Sanofi SA
  • Shimadzu Corporation
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Vector Laboratories
  • Waters Corporation
  • Z Biotech LLC
  • Zymeworks Inc.

人工智慧集成

我们正在利用可操作的专家内容和人工智慧工具来改变市场和竞争情报。

Global 特定产业SLM 的典型规范,而是建立了一个从全球专家收集的内容库,其中包括视讯录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口状况(成品和原始OEM)预测其竞争态势的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手,包括销货成本成本 (COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 竞赛

简介目录
Product Code: MCP37010

Global Glycomic Therapeutics Market to Reach US$395.7 Billion by 2030

The global market for Glycomic Therapeutics estimated at US$162.7 Billion in the year 2024, is expected to reach US$395.7 Billion by 2030, growing at a CAGR of 16.0% over the analysis period 2024-2030. Isolated Class, one of the segments analyzed in the report, is expected to record a 17.5% CAGR and reach US$278.7 Billion by the end of the analysis period. Growth in the Synthetic Class segment is estimated at 12.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$44.3 Billion While China is Forecast to Grow at 21.4% CAGR

The Glycomic Therapeutics market in the U.S. is estimated at US$44.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$87.4 Billion by the year 2030 trailing a CAGR of 21.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.6% and 14.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.7% CAGR.

Global "Glycomic Therapeutics" Market - Key Trends & Drivers Summarized

Why Are Glycomic Therapeutics Emerging as a Frontier in Precision Medicine?

Glycomic therapeutics-targeting and manipulating glycans (complex sugars) involved in cell signaling, immunity, and disease progression-represent a cutting-edge frontier in biomedical science. Glycans play vital roles in processes such as inflammation, tumor growth, pathogen recognition, and immune modulation. Unlike traditional small molecules or even genetic therapies, glycomics offers an entirely new layer of biological insight that can be used to diagnose, monitor, and treat complex diseases, including cancer, autoimmune disorders, and infectious diseases. As the pharmaceutical industry shifts toward personalized and systems-level approaches, the ability to analyze and target glycan structures opens the door to novel, highly selective therapies that go beyond conventional molecular targets. Glycomic therapeutics are increasingly viewed as the next step in unlocking precision medicine’s full potential.

What Scientific and Technological Advancements Are Enabling Glycan-Based Drug Development?

Breakthroughs in analytical chemistry, glycoengineering, and bioinformatics have been critical in making glycomic therapeutics commercially viable. Advanced mass spectrometry and high-throughput glycan profiling now allow researchers to characterize glycan structures at unprecedented depth and speed. Glycoengineering techniques enable the modification of glycoproteins to enhance therapeutic efficacy, reduce immunogenicity, or prolong drug half-life-capabilities especially valuable in biologics such as monoclonal antibodies. Furthermore, CRISPR and other gene editing tools are being used to regulate glycosylation pathways in engineered cell lines for controlled glycoprotein production. Bioinformatics platforms integrating glycomic, proteomic, and genomic data are helping researchers identify disease-specific glycan signatures, leading to better drug targeting and biomarker discovery. These technological synergies are rapidly transforming glycomics from an academic discipline into a commercially driven therapeutic space.

How Are Clinical Applications and Therapeutic Pipelines Evolving Globally?

Currently, glycomic therapeutics are making inroads across multiple therapeutic areas, particularly oncology, immunology, and virology. Cancer immunotherapies targeting abnormal glycan expressions on tumor cells-such as sialic acid ligands or glycan-dependent immune checkpoints-are under active investigation. In the field of rare genetic diseases, enzyme replacement therapies with optimized glycosylation are improving treatment outcomes. Companies are also developing glycan-based antivirals and vaccines, including COVID-19 candidates that target glycan shields on viral spike proteins. Inflammatory and autoimmune conditions are another key focus, as glycan-mediated cell adhesion and signaling play crucial roles in immune cell behavior. North America currently leads in terms of research funding and biopharmaceutical investment, but European institutions and startups are also active players. Asia-Pacific, particularly Japan and South Korea, is emerging as a significant innovation hub for glycan science and therapeutic development.

What Are the Key Market Drivers and Challenges for Glycomic Therapeutics?

The growth in the glycomic therapeutics market is driven by rising demand for precision treatments, expanding understanding of glycan biology, and increasing investment in novel biologics. Pharmaceutical companies are investing in this space to diversify their therapeutic portfolios and to address unmet medical needs with new mechanisms of action. Government research funding and public-private collaborations are also propelling foundational glycomics research into clinical pipelines. However, challenges remain-including the complexity of glycan structures, lack of standardized analytical platforms, limited commercial precedents, and high R&D costs. Additionally, regulatory pathways for glycomic-based drugs are still evolving, which can slow down approvals. Despite these obstacles, the field holds vast potential. As scientific clarity improves and commercial pathways mature, glycomic therapeutics are expected to become a foundational component of future drug development.

SCOPE OF STUDY:

The report analyzes the Glycomic Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Class (Isolated Class, Synthetic Class); Structure (Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure, Other Structures); Indication (Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication, Other Indications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Acuitas Therapeutics
  • Agilent Technologies Inc.
  • Alzheon Inc.
  • AMS Bio
  • Arrakis Therapeutics
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Bio-Techne Corporation
  • Bruker Corporation
  • F. Hoffmann-La Roche Ltd.
  • Genovis AB
  • GlaxoSmithKline plc
  • GlycoMar Limited
  • Grifols S.A.
  • Halozyme Therapeutics Inc.
  • ICON plc
  • Intellihep Ltd.
  • Ludger Ltd.
  • Merck KGaA
  • New England Biolabs Inc.
  • Protalix Biotherapeutics Inc.
  • RayBiotech Life Inc.
  • Sanofi S.A.
  • Shimadzu Corporation
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Vector Laboratories
  • Waters Corporation
  • Z Biotech LLC
  • Zymeworks Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Glycomic Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advancements in Glycobiology Research Throw Spotlight on Novel Therapeutic Applications
    • Rising Focus on Personalized Medicine and Biomarker Discovery Drives Demand for Glycan-Based Drugs
    • Integration of Glycomics with Immunotherapy Strengthens Business Case in Oncology and Autoimmune Disorders
    • Expansion of Biopharmaceutical Pipelines Accelerates Investment in Glyco-Engineering Technologies
    • Strategic Collaborations Between Academia and Biotech Fuel Innovation in Glycomics Research
    • Growing Applications in Vaccine Design and Infectious Disease Modulation Generate Market Interest
    • Use of AI in Glycan Mapping Enhances Precision in Drug Development and Disease Profiling
    • Emerging Role of Glycans in Neurological Disorders Expands Targeted R&D Investment
    • Supportive Regulatory Pathways for Rare and Orphan Drugs Accelerate Clinical Trials in Glycomic Therapies
    • Global Genomic and Proteomic Initiatives Drive Integration of Glycomic Data for RWE
    • Scalability Challenges and Complex Manufacturing Present Bottlenecks in Commercialization
    • Licensing and IP Portfolios Create Competitive Advantages for Early Glycomic Innovators
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Glycomic Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Glycomic Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Glycomic Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Glycomic Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Isolated Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Isolated Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Isolated Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Synthetic Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Synthetic Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Synthetic Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Thrombosis & Chemoprophylaxis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Thrombosis & Chemoprophylaxis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Thrombosis & Chemoprophylaxis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Anemia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Anemia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Anemia Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Cataract Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Cataract Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Cataract Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Gaucher's Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Gaucher's Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Gaucher's Disease Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for MPS-1 & IV Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for MPS-1 & IV Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for MPS-1 & IV Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Alzheimer's Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Alzheimer's Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Alzheimer's Disease Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Glycoproteins Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Glycoproteins Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Glycoproteins Structure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Targeting Sialic Acid Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Targeting Sialic Acid Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Targeting Sialic Acid Structure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Proteoglycans Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Proteoglycans Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for Proteoglycans Structure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Targeting Glycosaminoglycans Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Targeting Glycosaminoglycans Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: World 16-Year Perspective for Targeting Glycosaminoglycans Structure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Anchored Proteins & Heparin Based Glycans Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Anchored Proteins & Heparin Based Glycans Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: World 16-Year Perspective for Anchored Proteins & Heparin Based Glycans Structure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Targeting Glycosphingolipids Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Targeting Glycosphingolipids Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: World 16-Year Perspective for Targeting Glycosphingolipids Structure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Other Structures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Other Structures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: World 16-Year Perspective for Other Structures by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 56: USA Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: USA 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: USA 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: USA 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Canada 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Canada 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Canada 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • JAPAN
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Japan 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Japan 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Japan 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • CHINA
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 83: China Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: China 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: China 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: China 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • EUROPE
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Glycomic Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Glycomic Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Europe 16-Year Perspective for Glycomic Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Europe 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Europe 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Europe 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • FRANCE
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 104: France Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: France 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: France 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: France 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • GERMANY
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 113: Germany Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Germany 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Germany 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Germany 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 122: Italy Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Italy Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Italy 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 125: Italy Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Italy 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Italy 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 131: UK Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: UK Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: UK 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 134: UK Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: UK Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: UK 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 137: UK Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: UK 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 140: Spain Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Spain Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Spain 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 143: Spain Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Spain Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Spain 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 146: Spain Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Spain Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Spain 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 149: Russia Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Russia Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Russia 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 152: Russia Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Russia Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Russia 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 155: Russia Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Russia Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Russia 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Europe Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Europe 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Europe Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Europe 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Europe Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Europe 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Glycomic Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Asia-Pacific Historic Review for Glycomic Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Asia-Pacific 16-Year Perspective for Glycomic Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Asia-Pacific Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Asia-Pacific 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Asia-Pacific Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Asia-Pacific 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Asia-Pacific Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Asia-Pacific 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 179: Australia Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Australia Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Australia 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 182: Australia Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Australia Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Australia 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 185: Australia Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Australia Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Australia 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • INDIA
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 188: India Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: India Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: India 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 191: India Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: India Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: India 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 194: India Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: India Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: India 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 197: South Korea Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: South Korea Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: South Korea 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 200: South Korea Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: South Korea Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: South Korea 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 203: South Korea Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: South Korea Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: South Korea 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Asia-Pacific Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Asia-Pacific 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 209: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Asia-Pacific Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Rest of Asia-Pacific 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 212: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Rest of Asia-Pacific Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Rest of Asia-Pacific 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 215: Latin America Recent Past, Current & Future Analysis for Glycomic Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 216: Latin America Historic Review for Glycomic Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Latin America 16-Year Perspective for Glycomic Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 218: Latin America Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Latin America Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Latin America 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 221: Latin America Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Latin America Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Latin America 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 224: Latin America Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Latin America Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Latin America 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 227: Argentina Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Argentina Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Argentina 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 230: Argentina Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Argentina Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Argentina 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 233: Argentina Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Argentina Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Argentina 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 236: Brazil Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Brazil Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Brazil 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 239: Brazil Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Brazil Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Brazil 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 242: Brazil Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Brazil Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Brazil 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 245: Mexico Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Mexico Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Mexico 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 248: Mexico Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Mexico Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Mexico 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 251: Mexico Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Mexico Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Mexico 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Rest of Latin America Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Rest of Latin America 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 257: Rest of Latin America Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Rest of Latin America Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Rest of Latin America 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 260: Rest of Latin America Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Rest of Latin America Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Rest of Latin America 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 263: Middle East Recent Past, Current & Future Analysis for Glycomic Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 264: Middle East Historic Review for Glycomic Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Middle East 16-Year Perspective for Glycomic Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 266: Middle East Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Middle East Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Middle East 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 269: Middle East Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Middle East Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Middle East 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 272: Middle East Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Middle East Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Middle East 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 275: Iran Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Iran Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Iran 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 278: Iran Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Iran Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Iran 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 281: Iran Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Iran Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: Iran 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 284: Israel Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Israel Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: Israel 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 287: Israel Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Israel Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: Israel 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 290: Israel Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Israel Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Israel 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Saudi Arabia Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Saudi Arabia 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 296: Saudi Arabia Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Saudi Arabia Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Saudi Arabia 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 299: Saudi Arabia Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Saudi Arabia Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Saudi Arabia 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 302: UAE Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: UAE Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: UAE 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 305: UAE Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: UAE Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: UAE 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 308: UAE Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: UAE Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 310: UAE 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Middle East Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 313: Rest of Middle East 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 314: Rest of Middle East Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Middle East Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 316: Rest of Middle East 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 317: Rest of Middle East Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Rest of Middle East Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 319: Rest of Middle East 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • AFRICA
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 320: Africa Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Africa Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 322: Africa 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 323: Africa Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Africa Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 325: Africa 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 326: Africa Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Africa Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 328: Africa 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030

IV. COMPETITION